BAZ2A Biomarker Predicts Prostate Cancer Malignancy

BAZ2A Biomarker Predicts Prostate Cancer Malignancy
Findings from the “Early Onset Prostate Cancer” project, conducted by a collaboration among the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and many others, show that a key serum biomarker indicates the aggressiveness of prostate cancer. The protein is involved in epigenetic maintenance of tumor cells and is directly

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *